Evotec continues expansion

Evotec AG ended the 2017 first quarter with a broader revenue base, two new drug discovery agreements and Novo A/S as a strategic shareholder to help the company execute its strategy as a service provider and research partner for the global pharma industry.

Full text available to subscribers only. Click here for information on subscribing to MedNous.